PD 171026

Drug Profile

PD 171026

Latest Information Update: 31 Jul 2000

Price : $50

At a glance

  • Originator Pfizer
  • Class Antineoplastics
  • Mechanism of Action Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 31 Jul 2000 No-Development-Reported for Cancer in USA (Unknown route)
  • 21 Jun 2000 Warner-Lambert has merged with Pfizer
  • 11 Mar 1997 Preclinical development for Cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top